Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, MoonLake Immunotherapeutics (NASDAQ: MLTX) closed at $37.60 down -4.24% from its previous closing price of $39.26. In other words, the price has decreased by -$4.24 from its previous closing price. On the day, 0.57 million shares were traded.
Ratios:
For a deeper understanding of MoonLake Immunotherapeutics’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.11 and its Current Ratio is at 21.11. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on March 18, 2025, initiated with a Outperform rating and assigned the stock a target price of $67.
On January 17, 2025, Goldman Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $62 to $82.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 04 ’24 when BVF PARTNERS L P/IL sold 2,000,000 shares for $50.00 per share. The transaction valued at 100,003,200 led to the insider holds 1,287,768 shares of the business.
Sturge Simon sold 171,000 shares of MLTX for $9,186,120 on Oct 04 ’24. The Director now owns 171,980 shares after completing the transaction at $53.72 per share.
Stock Price History:
Over the past 52 weeks, MLTX has reached a high of $58.26, while it has fallen to a 52-week low of $31.42. The 50-Day Moving Average of the stock is -3.20%, while the 200-Day Moving Average is calculated to be -18.40%.
Shares Statistics:
A total of 63.08M shares are outstanding, with a floating share count of 52.94M. Insiders hold about 16.60% of the company’s shares, while institutions hold 100.13% stake in the company.
